U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H25N7O3
Molecular Weight 471.5111
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DABIGATRAN

SMILES

CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC3=C1C=CC(=C3)C(=O)N(CCC(O)=O)C4=NC=CC=C4

InChI

InChIKey=YBSJFWOBGCMAKL-UHFFFAOYSA-N
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)

HIDE SMILES / InChI
Molecular Formula C25H25N7O3
Molecular Weight 471.5111
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:13:22 UTC 2023
Edited
by admin
on Fri Dec 15 16:13:22 UTC 2023
Record UNII
I0VM4M70GC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DABIGATRAN
INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
BIBR 953 ZW
Code English
BIBR-953-ZW
Code English
N-((2-((P-AMIDINOANILINO)METHYL)-1-METHYL-5-BENZIMIDAZOLYL)CARBONYL)-N-2-PYRIDYL-.BETA.-ALANINE
Common Name English
DABIGATRAN [USAN]
Common Name English
3-{[(2-{[(4-Carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl](pyridin-2-yl)amino}propanoic acid
Systematic Name English
DABIGATRAN [MART.]
Common Name English
dabigatran [INN]
Common Name English
DABIGATRAN [VANDF]
Common Name English
.BETA.-ALANINE, N-((2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
Systematic Name English
DABIGATRAN [MI]
Common Name English
PRADAXA (DABIGATRAN)
Brand Name English
BIBR-953
Code English
Dabigatran [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
LOINC 68980-2
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
LOINC 74220-5
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
LIVERTOX NBK547924
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
Code System Code Type Description
SMS_ID
100000089438
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
EVMPD
SUB25417
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
MESH
C554682
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
ChEMBL
CHEMBL48361
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
NCI_THESAURUS
C73224
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
PUBCHEM
216210
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
DAILYMED
I0VM4M70GC
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
WIKIPEDIA
DABIGATRAN
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
RXCUI
1546356
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY RxNorm
CAS
211914-51-1
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
LACTMED
Dabigatran
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
MERCK INDEX
m4064
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID50175419
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
FDA UNII
I0VM4M70GC
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
DRUG BANK
DB14726
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
INN
8027
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
USAN
UU-125
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
HSDB
8062
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
CHEBI
70752
Created by admin on Fri Dec 15 16:13:22 UTC 2023 , Edited by admin on Fri Dec 15 16:13:22 UTC 2023
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
PROTHROMBIN
TARGET -> INHIBITOR
IDARUCIZUMAB
INHIBITOR -> TARGET
LIVER CARBOXYLESTERASE 1
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B15
METABOLIC ENZYME -> SUBSTRATE
HUMAN THROMBIN
TARGET -> INHIBITOR
REVERSIBLE
IC50
Related Record Type Details
Structure of .BETA.-ALANINE, N-((2-((ACETYLAMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
URINE
Structure of 1H-BENZIMIDAZOLE-5-CARBOXYLIC ACID, 2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
TRACE AMOUNT
PLASMA
Structure of 1H-BENZIMIDAZOLE-2-CARBOXYLIC ACID, 5-(((2-CARBOXYETHYL)-2-PYRIDINYLAMINO)CARBONYL)-1-METHYL-
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
PLASMA
Structure of 1H-BENZIMIDAZOLE-5-CARBOXYLIC ACID, 2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
URINE
Structure of .BETA.-ALANINE, N-((2-(HYDROXYMETHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA
Structure of .BETA.-ALANINE, N-((1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
URINE
Structure of .BETA.-ALANINE, N-((2-(HYDROXYMETHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
Structure of 1H-BENZIMIDAZOLE-2-CARBOXYLIC ACID, 5-(((2-CARBOXYETHYL)-2-PYRIDINYLAMINO)CARBONYL)-1-METHYL-
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
URINE
Structure of .BETA.-ALANINE, N-((2-(AMINOMETHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
URINE
Structure of 1H-BENZIMIDAZOLE-5-CARBOXAMIDE, 2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
Structure of .BETA.-D-GLUCOPYRANURONIC ACID, 1-(2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOLE-5-CARBOXYLATE)
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA; URINE
Structure of 1H-BENZIMIDAZOLE-2-CARBOXYLIC ACID, 5-(((2-CARBOXYETHYL)-2-PYRIDINYLAMINO)CARBONYL)-1-METHYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
Structure of 1H-BENZIMIDAZOLE-5-CARBOXAMIDE, 2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
URINE
Structure of .BETA.-ALANINE, N-((2-((ACETYLAMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA
Structure of DABIGATRAN ETEXILATE
PRODRUG -> METABOLITE ACTIVE
Structure of .BETA.-ALANINE, N-((2-((ACETYLAMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
Structure of .BETA.-ALANINE, N-((2-(HYDROXYMETHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
URINE
Structure of 1H-BENZIMIDAZOLE-5-CARBOXYLIC ACID, 2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
FECAL
Related Record Type Details
Structure of DABIGATRAN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

DOSE

Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966